Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MYH10

Gene summary for MYH10

Gene summary.

Gene information	Species	Human
	Gene symbol	MYH10
	Gene ID	4628
	Gene name	myosin heavy chain 10
	Gene Alias	NMMHC-IIB
	Cytomap	17p13.1
	Gene Type	protein-coding
	GO ID	GO:0000278
	UniProtAcc	G1UI33

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
4628	MYH10	AEH-subject1	Human	Endometrium	AEH	4.15e-04	1.70e-01	-0.3059
4628	MYH10	AEH-subject2	Human	Endometrium	AEH	1.93e-02	6.96e-02	-0.2525
4628	MYH10	AEH-subject3	Human	Endometrium	AEH	3.54e-02	1.58e-01	-0.2576
4628	MYH10	AEH-subject4	Human	Endometrium	AEH	2.48e-10	4.30e-01	-0.2657
4628	MYH10	EEC-subject1	Human	Endometrium	EEC	6.33e-18	4.84e-01	-0.2682
4628	MYH10	EEC-subject3	Human	Endometrium	EEC	9.30e-03	-3.64e-02	-0.2525
4628	MYH10	EEC-subject4	Human	Endometrium	EEC	9.19e-05	2.37e-01	-0.2571
4628	MYH10	GSM5276934	Human	Endometrium	EEC	1.45e-04	-1.85e-01	-0.0913
4628	MYH10	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	6.07e-14	-8.54e-04	-0.1869
4628	MYH10	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	3.08e-14	1.11e-02	-0.1875
4628	MYH10	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	3.08e-18	4.53e-02	-0.1883
4628	MYH10	GSM6177621_NYU_UCEC2_lib1_lib1	Human	Endometrium	EEC	6.71e-13	1.71e-01	-0.1934
4628	MYH10	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	1.61e-19	7.11e-02	-0.1917
4628	MYH10	GSM6177622_NYU_UCEC3_lib2_lib2	Human	Endometrium	EEC	2.85e-22	7.09e-02	-0.1916
4628	MYH10	GSM6177623_NYU_UCEC3_Vis	Human	Endometrium	EEC	2.40e-04	2.38e-01	-0.1269
4628	MYH10	LZE4T	Human	Esophagus	ESCC	4.34e-16	6.26e-01	0.0811
4628	MYH10	LZE7T	Human	Esophagus	ESCC	1.12e-08	7.43e-01	0.0667
4628	MYH10	LZE24T	Human	Esophagus	ESCC	7.14e-09	2.75e-01	0.0596
4628	MYH10	LZE21T	Human	Esophagus	ESCC	2.17e-04	2.44e-01	0.0655
4628	MYH10	P1T-E	Human	Esophagus	ESCC	3.34e-03	2.93e-01	0.0875

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:002260415	Endometrium	AEH	regulation of cell morphogenesis	79/2100	309/18723	1.04e-12	2.24e-10	79
GO:190495115	Endometrium	AEH	positive regulation of establishment of protein localization	74/2100	319/18723	7.05e-10	6.51e-08	74
GO:005122215	Endometrium	AEH	positive regulation of protein transport	66/2100	303/18723	7.79e-08	3.99e-06	66
GO:003103210	Endometrium	AEH	actomyosin structure organization	46/2100	196/18723	8.00e-07	2.91e-05	46
GO:00009108	Endometrium	AEH	cytokinesis	40/2100	173/18723	6.01e-06	1.49e-04	40
GO:00300488	Endometrium	AEH	actin filament-based movement	31/2100	127/18723	2.10e-05	4.14e-04	31
GO:00083609	Endometrium	AEH	regulation of cell shape	34/2100	154/18723	7.85e-05	1.18e-03	34
GO:00616403	Endometrium	AEH	cytoskeleton-dependent cytokinesis	24/2100	100/18723	2.27e-04	2.75e-03	24
GO:00507087	Endometrium	AEH	regulation of protein secretion	49/2100	268/18723	3.83e-04	4.12e-03	49
GO:00507149	Endometrium	AEH	positive regulation of protein secretion	28/2100	137/18723	1.17e-03	1.01e-02	28
GO:00002813	Endometrium	AEH	mitotic cytokinesis	17/2100	71/18723	1.82e-03	1.45e-02	17
GO:00508086	Endometrium	AEH	synapse organization	67/2100	426/18723	2.67e-03	1.94e-02	67
GO:00716927	Endometrium	AEH	protein localization to extracellular region	58/2100	368/18723	4.72e-03	3.00e-02	58
GO:00093068	Endometrium	AEH	protein secretion	56/2100	359/18723	6.71e-03	3.94e-02	56
GO:00355928	Endometrium	AEH	establishment of protein localization to extracellular region	56/2100	360/18723	7.10e-03	4.09e-02	56
GO:002260416	Endometrium	EEC	regulation of cell morphogenesis	78/2168	309/18723	1.45e-11	2.28e-09	78
GO:190495116	Endometrium	EEC	positive regulation of establishment of protein localization	74/2168	319/18723	2.90e-09	2.10e-07	74
GO:005122216	Endometrium	EEC	positive regulation of protein transport	66/2168	303/18723	2.55e-07	1.09e-05	66
GO:003103214	Endometrium	EEC	actomyosin structure organization	46/2168	196/18723	1.94e-06	5.80e-05	46
GO:000091013	Endometrium	EEC	cytokinesis	40/2168	173/18723	1.29e-05	2.60e-04	40

Page: 1 2 3 4 5 6 7 8 9 10

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0453026	Endometrium	AEH	Tight junction	54/1197	169/8465	1.99e-09	3.80e-08	2.78e-08	54
hsa0513026	Endometrium	AEH	Pathogenic Escherichia coli infection	50/1197	197/8465	1.72e-05	1.86e-04	1.36e-04	50
hsa0481018	Endometrium	AEH	Regulation of actin cytoskeleton	50/1197	229/8465	9.08e-04	5.78e-03	4.23e-03	50
hsa048144	Endometrium	AEH	Motor proteins	42/1197	193/8465	2.41e-03	1.42e-02	1.04e-02	42
hsa04530112	Endometrium	AEH	Tight junction	54/1197	169/8465	1.99e-09	3.80e-08	2.78e-08	54
hsa05130112	Endometrium	AEH	Pathogenic Escherichia coli infection	50/1197	197/8465	1.72e-05	1.86e-04	1.36e-04	50
hsa0481019	Endometrium	AEH	Regulation of actin cytoskeleton	50/1197	229/8465	9.08e-04	5.78e-03	4.23e-03	50
hsa0481411	Endometrium	AEH	Motor proteins	42/1197	193/8465	2.41e-03	1.42e-02	1.04e-02	42
hsa0453027	Endometrium	EEC	Tight junction	54/1237	169/8465	6.56e-09	1.27e-07	9.46e-08	54
hsa0513027	Endometrium	EEC	Pathogenic Escherichia coli infection	51/1237	197/8465	1.98e-05	2.28e-04	1.70e-04	51
hsa0481024	Endometrium	EEC	Regulation of actin cytoskeleton	49/1237	229/8465	3.20e-03	1.78e-02	1.33e-02	49
hsa048142	Endometrium	EEC	Motor proteins	42/1237	193/8465	4.43e-03	2.39e-02	1.78e-02	42
hsa0453036	Endometrium	EEC	Tight junction	54/1237	169/8465	6.56e-09	1.27e-07	9.46e-08	54
hsa0513036	Endometrium	EEC	Pathogenic Escherichia coli infection	51/1237	197/8465	1.98e-05	2.28e-04	1.70e-04	51
hsa0481034	Endometrium	EEC	Regulation of actin cytoskeleton	49/1237	229/8465	3.20e-03	1.78e-02	1.33e-02	49
hsa048143	Endometrium	EEC	Motor proteins	42/1237	193/8465	4.43e-03	2.39e-02	1.78e-02	42
hsa05130211	Esophagus	ESCC	Pathogenic Escherichia coli infection	142/4205	197/8465	8.21e-11	1.06e-09	5.42e-10	142
hsa04530211	Esophagus	ESCC	Tight junction	105/4205	169/8465	6.73e-04	2.23e-03	1.14e-03	105
hsa0481028	Esophagus	ESCC	Regulation of actin cytoskeleton	133/4205	229/8465	5.94e-03	1.48e-02	7.56e-03	133
hsa05130310	Esophagus	ESCC	Pathogenic Escherichia coli infection	142/4205	197/8465	8.21e-11	1.06e-09	5.42e-10	142

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MYH10

SNV

Missense_Mutation

c.5258C>T

p.Ser1753Phe

p.S1753F

P35580

protein_coding

deleterious(0.01)

benign(0.067)

TCGA-A2-A0CT-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

MYH10

SNV

Missense_Mutation

rs778892637

c.1999G>A

p.Glu667Lys

p.E667K

P35580

protein_coding

deleterious(0.03)

possibly_damaging(0.757)

TCGA-A2-A0CT-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

MYH10

SNV

Missense_Mutation

c.2581C>T

p.Arg861Trp

p.R861W

P35580

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-A8-A09Q-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozole

MYH10

SNV

Missense_Mutation

c.1750G>T

p.Asp584Tyr

p.D584Y

P35580

protein_coding

deleterious(0)

possibly_damaging(0.845)

TCGA-A8-A0AB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

MYH10

SNV

Missense_Mutation

c.4484N>G

p.Ser1495Cys

p.S1495C

P35580

protein_coding

deleterious(0.02)

probably_damaging(0.981)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYH10

SNV

Missense_Mutation

novel

c.4007N>C

p.Lys1336Thr

p.K1336T

P35580

protein_coding

tolerated(0.05)

probably_damaging(0.962)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYH10

SNV

Missense_Mutation

c.4396N>A

p.Asp1466Asn

p.D1466N

P35580

protein_coding

tolerated(0.09)

benign(0.105)

TCGA-AN-A0XN-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

MYH10

SNV

Missense_Mutation

c.615A>T

p.Arg205Ser

p.R205S

P35580

protein_coding

tolerated(0.2)

benign(0.015)

TCGA-AR-A24Q-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

MYH10

SNV

Missense_Mutation

c.614G>A

p.Arg205Lys

p.R205K

P35580

protein_coding

tolerated(1)

benign(0.001)

TCGA-AR-A24Q-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

MYH10

SNV

Missense_Mutation

rs776217752

c.4927N>T

p.Arg1643Trp

p.R1643W

P35580

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-AR-A256-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1